Advancing Knowledge About The Treatment of Advanced Prostate Cancer, Highlights from GU ASCO 2021 – Praful Ravi

Praful Ravi, MB, BChir, MRCP, and Alicia Morgans, MD, MPH highlight several prostate cancer abstracts from GU ASCO 2021 and discuss the clinical landscape for treating prostate cancer. They highlight results of the ACIS trial assessing the combination of apalutamide + abiraterone acetate as compared to abiraterone acetate alone in patients with chemo-naive metastatic castration-resistant…

Read the full article here

Source: UroToday

Categories: General Medicine News, Latest Headlines

Tags: ASCOGU21, ProstateCancer, WatchNow

Tweets with this article

UroToday.com

Advancing knowledge about the treatment of advanced #ProstateCancer, highlights from #ASCOGU21. Praful Ravi MB, BChir, MRCP @DanaFarber joins @CaPsurvivorship @NUFeinbergMed discussing the clinical landscape for treating prostate cancer. #WatchNow > https://t.co/qtlTCyY8oE @ASCO https://t.co/5VaCOmrzNe

Navigating the Nuances: Exploring Imaging Options and Impact to Treatment Strategies in nmCPRC – Ryan Malone

Zach Klaassen and Ryan Malone discuss the management of Nonmetastatic castration-resistant prostate cancer (nmCRPC), focusing on the evolving role of PSMA PET imaging. They highlight…

UroToday.com April 23, 2024

Secondary Bladder Cancers Following Prostate Cancer Treatment Modalities – Expert Commentary

Bladder cancer, external beam radiation therapy (EBRT), brachytherapy (BT), risk of bladder cancer after different prostate cancer treatment modalities, Secondary Bladder Cancers Following Prostate Cancer…

UroToday.com April 23, 2024

Critical Evaluation of Artificial Intelligence as a Digital Twin of Pathologists for Prostate Cancer Pathology – Beyond the Abstract

Prostate Cancer, Artificial Intelligence in prostate cancer treatment, Artificial Intelligence as a Digital Twin of Pathologists for Prostate Cancer, cribriform morphologies, prostate tissue stained with…

UroToday.com April 22, 2024

The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer – Neal Shore

Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed…

UroToday.com April 22, 2024

How to Report PSMA PET – Beyond the Abstract

methods to convey PSMA-PET/CT results, prostate cancer, Prostate-Specific Membrane Antigen (PSMA), PSMA PET, 177Lu-PSMA-SPECT, biochemical recurrence (BCR), PROMISE, PRIMARY, PSMA_RADS, E-PSMA.

UroToday.com April 22, 2024

The Critical Intersection of Androgen Receptor Pathways and Cell Cycle Regulation in Prostate Cancer Therapy – Rana McKay

Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…

UroToday.com April 22, 2024

Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High – Sumit Subudhi

Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…

UroToday.com April 22, 2024

Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive NMIBC – Stephen Boorjian

Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector…

UroToday.com April 22, 2024

Tumor Heterogeneity Selective Pressure – Why We Need New Targets? – Oliver Sartor

Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC The Biological Basis of Metastatic Prostate Cancer – The Unmet Medical…

UroToday.com April 22, 2024

Local Therapy on Clinically Lymph Node-positive Prostate Cancer: A Systematic Review and Meta-analysis – Beyond the Abstract

prostate cancer, Lymph Node-positive Prostate Cancer, androgen deprivation therapy (ADT), PSMA-PET/CT, cN1 disease, detection of lymph node metastasis, PSMA-PET/CT.

UroToday.com April 22, 2024

Related Articles